Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263897 | 0.91 | CYP3A4 (0.54) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL264429 | 0.89 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL263368 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL20328195 | 0.87 | ENPP2 (0.51) | ENPP2 | |
| SCHEMBL263890 | 0.87 | MAPT (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL265165 | 0.87 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL264891 | 0.86 | MAPT (0.52) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL265919 | 0.86 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL264256 | 0.85 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19POLB | |
| SCHEMBL265992 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | claimed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | claimed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | claimed |
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PREC MEDICINES INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | disclosed |
| WO-2018118101-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, RYR1 | CYP3A4 1593/4885CYP2D6 759/4885CYP2C9 1559/4885 |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | APP, CACNA1G, CACNA1B | CYP3A4 3284/4885CYP2D6 2414/4885CYP2C9 2207/4885 |
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | CYP3A4 4726/4885CYP2D6 4624/4885CYP2C9 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.